Want to see JP:4588 full AI Analyst Report?
4588 Stock Chart & Stats
¥953.00
-¥1.00(-0.20%)
At close: 4:00 PM EST
¥953.00
-¥1.00(-0.20%)
Day’s Range― - ―
52-Week Range¥570.00 - ¥3,695.00
Previous CloseN/A
Volume332.10K
Average Volume (3M)1.52M
Market Cap
¥86.56B
Enterprise Value¥67.07B
Total Cash (Recent Filing)¥1.39B
Total Debt (Recent Filing)¥366.79M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-93.11
Shares Outstanding29,309,700
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet Strength / Low LeverageThe company's expanded equity and assets with modest debt (debt/equity ~0.12) provide a durable buffer against cash burn. This balance-sheet capacity improves access to financing, supports ongoing R&D spend and partnering negotiations, and reduces immediate liquidity pressure over months.
High Gross Margins On Reported RevenueVery high gross margins imply revenue has low direct costs, so any recurring or partner-derived revenue can flow relatively quickly toward covering fixed R&D and G&A. Structurally, this raises leverage on future revenue growth and improves the economics of licensing or scaled sales if achieved.
Partnership-driven, Capital-efficient Business ModelA model centered on collaborations, milestones and grants reduces the need for full commercial infrastructure and can deliver non-dilutive or staged funding. Over months this structure helps de-risk late-stage development and preserves capital versus self-commercialization strategies.
Bears Say
Severe Revenue CollapseA multi-year collapse in revenue signals lost or failed programs, waning partner income, or discontinued streams. Such a structural decline undermines the firm's ability to cover fixed R&D and G&A, makes recovery harder without new partners or approvals, and damages long-term sustainability.
Persistent Heavy Cash BurnConsistent large operating outflows mean the business cannot self-fund development and will rely on external capital. Over 2–6 months this raises dilution and refinancing risk, constrains trial execution flexibility, and can slow progress absent new funding or partner milestone receipts.
Ongoing Large Operating Losses And Negative ROESustained operating losses and negative ROE erode equity value and indicate no current path to profitability. Structural losses necessitate strategy shifts or successful partnering/commercial outcomes; absent these, the firm faces long-term solvency and shareholder dilution risks.
Oncolys BioPharma, Inc. News
4588 FAQ
What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥570.00 and its highest was ¥3695.00 in the past 12 months.
What is Oncolys BioPharma, Inc.’s market cap?
Oncolys BioPharma, Inc.’s market cap is ¥86.56B.
When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
Oncolys BioPharma, Inc.’s upcoming earnings report date is Jul 31, 2026 which is in 29 days.
How were Oncolys BioPharma, Inc.’s earnings last quarter?
Oncolys BioPharma, Inc. released its earnings results on May 08, 2026. The company reported -¥14.16 earnings per share for the quarter, missing the consensus estimate of N/A by -¥14.16.
Is Oncolys BioPharma, Inc. overvalued?
According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued.
Does Oncolys BioPharma, Inc. pay dividends?
Oncolys BioPharma, Inc. does not currently pay dividends.
What is Oncolys BioPharma, Inc.’s EPS estimate?
Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolys BioPharma, Inc. have?
Oncolys BioPharma, Inc. has 29,309,700 shares outstanding.
What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
Oncolys BioPharma, Inc. reported an EPS of -¥14.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.819%.
Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
Currently, no hedge funds are holding shares in JP:4588
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
Technical Analysis
Options Prices
Currently, No data available
---